Literature DB >> 33412571

An influenza HA stalk reactive polymeric IgA antibody exhibits anti-viral function regulated by binary interaction between HA and the antibody.

Kaori Sano1,2, Shinji Saito3, Tadaki Suzuki1, Osamu Kotani4, Akira Ainai1, Elly van Riet3, Koshiro Tabata1, Kumpei Saito1, Yoshimasa Takahashi5, Masaru Yokoyama4, Hironori Sato4, Takahiro Maruno6, Kaede Usami6, Susumu Uchiyama6,7, Kiyoko Ogawa-Goto8, Hideki Hasegawa1,2,3,9.   

Abstract

IgA antibodies, which are secreted onto the mucosal surface as secretory IgA antibodies (SIgAs), play an important role in preventing influenza virus infection. A recent study reported that anti-hemagglutinin (HA) head-targeting antibodies increase anti-viral functions such as hemagglutination inhibition (HI) and virus neutralization (NT), in addition to HA binding activity (reactivity) via IgA polymerization. However, the functional properties of anti-viral IgA antibodies with mechanisms of action distinct from those of anti-HA head-targeting antibodies remain elusive. Here, we characterized the functional properties of IgG, monomeric IgA, and polymeric IgA anti-HA stalk-binding clones F11 and FI6, and B12 (a low affinity anti-HA stalk clone), as well as Fab-deficientFab) IgA antibodies. We found that IgA polymerization impacts the functional properties of anti-HA stalk antibodies. Unlike anti-HA head antibodies, the anti-viral functions of anti-HA stalk antibodies were not simply enhanced by IgA polymerization. The data suggest that two modes of binding (Fab paratope-mediated binding to the HA stalk, and IgA Fc glycan-mediated binding to the HA receptor binding site (RBS)) occur during interaction between anti-stalk HA IgA antibodies and HA. In situations where Fab paratope-mediated binding to the HA stalk exceeded IgA Fc glycan-mediated binding to HA RBS, IgA polymerization increased anti-viral functions. By contrast, when IgA Fc glycan-mediated binding to the HA RBS was dominant, anti-viral activity will fall upon IgA polymerization. In summary, the results suggest that coordination between these two independent binding modules determines whether IgA polymerization has a negative or positive effect on the anti-viral functions of anti-HA stalk IgA antibodies.

Entities:  

Year:  2021        PMID: 33412571      PMCID: PMC7790537          DOI: 10.1371/journal.pone.0245244

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  59 in total

1.  COMPARISONS OF SEROLOGIC AND FEBRILE RESPONSES IN HUMANS TO VACCINATION WITH INFLUENZA A VIRUSES OR THEIR HEMAGGLUTININS.

Authors:  F M DAVENPORT; A V HENNESSY; F M BRANDON; R G WEBSTER; C D BARRETT; G O LEASE
Journal:  J Lab Clin Med       Date:  1964-01

2.  Calculations and Publication-Quality Illustrations for Analytical Ultracentrifugation Data.

Authors:  Chad A Brautigam
Journal:  Methods Enzymol       Date:  2015-06-16       Impact factor: 1.600

Review 3.  Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.

Authors:  Hideki Hasegawa; Takeshi Ichinohe; Shin-ichi Tamura; Takeshi Kurata
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

4.  Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus.

Authors:  Tadaki Suzuki; Akira Kawaguchi; Akira Ainai; Shin-ichi Tamura; Ryo Ito; Pretty Multihartina; Vivi Setiawaty; Krisna Nur Andriana Pangesti; Takato Odagiri; Masato Tashiro; Hideki Hasegawa
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

5.  Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus.

Authors:  Yasuko Asahi-Ozaki; Tomoki Yoshikawa; Yoichiro Iwakura; Yujiro Suzuki; Shin-Ichi Tamura; Takeshi Kurata; Tetsutaro Sata
Journal:  J Med Virol       Date:  2004-10       Impact factor: 2.327

6.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB.

Authors:  James A Maier; Carmenza Martinez; Koushik Kasavajhala; Lauren Wickstrom; Kevin E Hauser; Carlos Simmerling
Journal:  J Chem Theory Comput       Date:  2015-07-23       Impact factor: 6.006

7.  Increased HIV-1 sensitivity to neutralizing antibodies by mutations in the Env V3-coding region for resistance to CXCR4 antagonists.

Authors:  Yuta Hikichi; Masaru Yokoyama; Taichiro Takemura; Masayuki Fujino; Sei Kumakura; Yosuke Maeda; Naoki Yamamoto; Hironori Sato; Tetsuro Matano; Tsutomu Murakami
Journal:  J Gen Virol       Date:  2016-07-01       Impact factor: 3.891

Review 8.  The human antibody response to influenza A virus infection and vaccination.

Authors:  Florian Krammer
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

9.  A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus.

Authors:  Ying Wu; MyungSam Cho; David Shore; Manki Song; JungAh Choi; Tao Jiang; Yong-Qiang Deng; Melissa Bourgeois; Lynn Almli; Hua Yang; Li-Mei Chen; Yi Shi; Jianxu Qi; An Li; Kye Sook Yi; MinSeok Chang; Jin Soo Bae; HyunJoo Lee; JiYoung Shin; James Stevens; SeoungSuh Hong; Cheng-Feng Qin; George F Gao; Shin Jae Chang; Ruben O Donis
Journal:  Nat Commun       Date:  2015-07-21       Impact factor: 14.919

10.  Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.

Authors:  Akira Ainai; Elly van Riet; Ryo Ito; Kazuyuki Ikeda; Kyosuke Senchi; Tadaki Suzuki; Shin-Ichi Tamura; Hideki Asanuma; Takato Odagiri; Masato Tashiro; Takeshi Kurata; Pretty Multihartina; Vivi Setiawaty; Krisna Nur Andriana Pangesti; Hideki Hasegawa
Journal:  Microbiol Immunol       Date:  2020-01-20       Impact factor: 1.955

View more
  1 in total

1.  Structure-Guided Creation of an Anti-HA Stalk Antibody F11 Derivative That Neutralizes Both F11-Sensitive and -Resistant Influenza A(H1N1)pdm09 Viruses.

Authors:  Osamu Kotani; Yasushi Suzuki; Shinji Saito; Akira Ainai; Akira Ueno; Takuya Hemmi; Kaori Sano; Koshiro Tabata; Masaru Yokoyama; Tadaki Suzuki; Hideki Hasegawa; Hironori Sato
Journal:  Viruses       Date:  2021-08-31       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.